Top

Published in:

Open Access 01-12-2022 | COVID-19 | Research

The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial

Authors: Gholamreza Askari, Amirhossein Sahebkar, Davood Soleimani, Atena Mahdavi, Sahar Rafiee, Muhammed Majeed, Farzin Khorvash, Bijan Iraj, Mahshid Elyasi, Mohammad Hossein Rouhani, Mohammad Bagherniya

Published in: Trials | Issue 1/2022

Abstract

Background

COVID-19 pandemic has made the disease a major global problem by creating a significant burden on health, economic, and social status. To date, there are no effective and approved medications for this disease. Curcumin as an anti-inflammatory agent can have a positive effect on the control of COVID-19 complications. This study aimed to assess the efficacy of curcumin-piperine supplementation on clinical symptoms, duration, severity, and inflammatory factors in patients with COVID-19.

Methods

Forty-six outpatients with COVID-19 disease were randomly allocated to receive two capsules of curcumin-piperine; each capsule contained 500 mg curcumin plus 5 mg piperine or placebo for 14 days.

Results

Mean changes in complete blood count, liver enzymes, blood glucose levels, lipid parameters, kidney function, and c-reactive protein (CRP) were not significantly different between the two groups. There was a significant improvement in health status, including dry cough, sputum cough, ague, sore throat, weakness, muscular pain, headache, and dyspnea at week 2 in both curcumin-piperine and placebo groups (P value < 0.05); however, the improvement in weakness was more in the curcumin-piperine group than with placebo group (P value 025).

Conclusion

The present study results showed that curcumin-piperine co-supplementation in outpatients with COVID-19 could significantly reduce weakness. However, in this study, curcumin-piperine co-supplementation could not significantly affect the other indices, including biochemical and clinical indices.

Trial registration

Iranian Registry of Clinical Trials IRCT20121216011763N46. 2020-10-31

Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg (London, England). 2020;76:71–6. https://doi.org/10.1016/j.ijsu.2020.02.034.CrossRef

BourBour F, Mirzaei Dahka S, Gholamalizadeh M, Akbari ME, Shadnoush M, Haghighi M, et al. Nutrients in prevention, treatment, and management of viral infections; special focus on Coronavirus. Arch Physiol Biochem. 2020:1–10. https://doi.org/10.1080/13813455.2020.1791188.

Rothenberg E. Coronavirus disease 19 from the perspective of ageing with focus on nutritional status and nutrition management—a narrative review. Nutrients. 2021;13(4):1294. https://doi.org/10.3390/nu13041294.CrossRefPubMedPubMedCentral

Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med. 2020;20(2):124. https://doi.org/10.7861/clinmed.2019-coron.CrossRef

Brem A, Viardot E, Nylund PA. Implications of the coronavirus (COVID-19) outbreak for innovation: which technologies will improve our lives? Technol Forecast Soc Chang. 2021;163:120451. https://doi.org/10.1016/j.techfore.2020.120451.CrossRef

Zahedipour F, Hosseini SA, Sathyapalan T, Majeed M, Jamialahmadi T, Al-Rasadi K, et al. Potential effects of curcumin in the treatment of COVID-19 infection. Phytother Res. 2020;34(11):2911–20. https://doi.org/10.1002/ptr.6738.CrossRefPubMedPubMedCentral

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4. https://doi.org/10.1016/S0140-6736(20)30628-0.CrossRefPubMedPubMedCentral

Saber-Moghaddam N, Salari S, Hejazi S, Amini M, Taherzadeh Z, Eslami S, et al. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: an open label nonrandomized clinical trial. Phytother Res. 2021. https://doi.org/10.1002/ptr.7004.

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England). 2020;395(10223):e30. https://doi.org/10.1016/S0140-6736(20)30304-4.CrossRef

10.

Farhood B, Mortezaee K, Goradel NH, Khanlarkhani N, Salehi E, Nashtaei MS, et al. Curcumin as an anti-inflammatory agent: implications to radiotherapy and chemotherapy. J Cell Physiol. 2019;234(5):5728–40. https://doi.org/10.1002/jcp.27442.CrossRefPubMed

11.

Ternullo S, Gagnat E, Julin K, Johannessen M, Basnet P, Vanić Ž, et al. Liposomes augment biological benefits of curcumin for multitargeted skin therapy. Eur J Pharm Biopharm. 2019;144:154–64. https://doi.org/10.1016/j.ejpb.2019.09.016.CrossRefPubMed

12.

Rafiq S, Raza MH, Younas M, Naeem F, Adeeb R, Iqbal J, et al. Molecular targets of curcumin and future therapeutic role in leukemia. J Biosci Med. 2018;6(04):33. https://doi.org/10.4236/JBM.2018.64003.CrossRef

13.

Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39(3):283–99. https://doi.org/10.1111/j.1440-1681.2011.05648.x.CrossRefPubMedPubMedCentral

14.

Keihanian F, Saeidinia A, Bagheri RK, Johnston TP, Sahebkar A. Curcumin, hemostasis, thrombosis, and coagulation. J Cell Physiol. 2018;233(6):4497–511. https://doi.org/10.1002/jcp.26249.CrossRefPubMed

15.

Jain SK, Rains J, Croad J, Larson B, Jones K. Curcumin supplementation lowers TNF-α, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-α, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal. 2009;11(2):241–9. https://doi.org/10.1089/ars.2008.2140.CrossRefPubMedPubMedCentral

16.

Avasarala S, Zhang F, Liu G, Wang R, London SD, London L. Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome. PLoS One. 2013;8(2):e57285. https://doi.org/10.1371/journal.pone.0134982.CrossRefPubMedPubMedCentral

17.

Maurya VK, Kumar S, Prasad AK, Bhatt ML, Saxena SK. Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor. Virusdisease. 2020;31(2):179–93. https://doi.org/10.1007/s13337-020-00598-8.CrossRefPubMedPubMedCentral

18.

Rocha FAC, de Assis MR. Curcumin as a potential treatment for COVID-19. Phytother Res. 2020;34(9):2085–7. https://doi.org/10.1002/ptr.6745.CrossRefPubMedPubMedCentral

19.

Thimmulappa RK, Kumar MNK, Shivamallu C, Subramaniam KT, Radhakrishnan A, Suresh B, et al. Antiviral and immunomodulatory activity of curcumin: a case for prophylactic therapy for COVID-19. Heliyon. 2021;7(2):e06350. https://doi.org/10.1016/j.heliyon.2021.e06350.CrossRefPubMedPubMedCentral

20.

Bagherniya M, Khedmatgozar H, Fakheran O, Xu S, Johnston TP, Sahebkar A. Medicinal plants and bioactive natural products as inhibitors of NLRP3 inflammasome. Phytother Res. 2021;35(9):4804–33. https://doi.org/10.1002/ptr.7118.CrossRefPubMed

21.

Alikiaii B, Bagherniya M, Askari G, Sathyapalan T, Sahebkar A. Evaluation of the effect of curcumin on pneumonia: a systematic review of preclinical studies. Phytother Res. 2021;35(4):1939–52. https://doi.org/10.1002/ptr.6939.CrossRefPubMed

22.

Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int. 2014;2014:186864. https://doi.org/10.1155/2014/186864.CrossRefPubMedCentral

23.

Soni VK, Mehta A, Ratre YK, Tiwari AK, Amit A, Singh RP, et al. Curcumin, a traditional spice component, can hold the promise against COVID-19? Eur J Pharmacol. 2020;886:173551. https://doi.org/10.1016/j.ejphar.2020.173551.CrossRefPubMedPubMedCentral

24.

Pawar KS, Mastud RN, Pawar SK, Pawar SS, Bhoite RR, Bhoite RR, et al. Oral curcumin with piperine as adjuvant therapy for the treatment of COVID-19: a randomized clinical trial. Front Pharmacol. 2021;12:669362. https://doi.org/10.3389/fphar.2021.669362.CrossRefPubMedPubMedCentral

25.

Babaei F, Nassiri-Asl M, Hosseinzadeh H. Curcumin (a constituent of turmeric): New treatment option against COVID-19. Food Sci Nutr. 2020;8(10):5215–27. https://doi.org/10.1002/fsn3.1858.CrossRefPubMedPubMedCentral

26.

Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, Guest PC, Majeed M, Mohammadi A, et al. Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: a systematic review of clinical trials. Nutrients. 2022;14(2):256. https://doi.org/10.3390/nu14020256.CrossRefPubMedPubMedCentral

27.

Miryan M, Soleimani D, Askari G, Jamialahmadi T, Guest PC, Bagherniya M, et al. Curcumin and piperine in COVID-19: a promising duo to the rescue? Adv Exp Med Biol. 2021;1327:197–204. https://doi.org/10.1007/978-3-030-71697-4_16.CrossRefPubMed

28.

Subhan F, Khalil AAK, Zeeshan M, Haider A, Tauseef I, Haleem SK, et al. Curcumin: from ancient spice to modern anti-viral drug in COVID-19 pandemic. Life Sci. 2020;1(supplement):5.CrossRef

29.

Valizadeh H, Abdolmohammadi-Vahid S, Danshina S, Gencer MZ, Ammari A, Sadeghi A, et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients. Int Immunopharmacol. 2020;89(Pt B):107088. https://doi.org/10.1016/j.intimp.2020.107088.CrossRefPubMedPubMedCentral

30.

Bhutani MK, Bishnoi M, Kulkarni SK. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav. 2009;92(1):39–43. https://doi.org/10.1016/j.pbb.2008.10.007.CrossRefPubMed

31.

Kulkarni SK, Bhutani MK, Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology. 2008;201(3):435–42. https://doi.org/10.1007/s00213-008-1300-y.CrossRefPubMed

32.

Miryan M, Soleimani D, Askari G, Jamialahmadi T, Guest PC, Bagherniya M, et al. Curcumin and piperine in COVID-19: a promising duo to the rescue? In: Identification of biomarkers, new treatments, and vaccines for COVID-19. Switzerland: Springer; 2021. p. 197–204.

33.

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18. https://doi.org/10.1021/mp700113r.CrossRefPubMed

34.

Miryan M, Bagherniya M, Sahebkar A, Soleimani D, Rouhani MH, Iraj B, et al. Effects of curcumin-piperine co-supplementation on clinical signs, duration, severity, and inflammatory factors in patients with COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):1–2. https://doi.org/10.1186/s13063-020-04924-9.CrossRef

35.

Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians. Clin Microbiol Infect. 2020;26(7):842–7. https://doi.org/10.1016/j.cmi.2020.04.023.CrossRefPubMedPubMedCentral

36.

Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, et al. Treatment options for COVID-19: a review. Front Med (Lausanne). 2020;7:480. https://doi.org/10.3389/fmed.2020.00480.CrossRef

37.

Ahmadi R, Salari S, Sharifi MD, Reihani H, Rostamiani MB, Behmadi M, et al. Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: a randomized triple-blind placebo-controlled clinical trial. Food Sci Nutr. 2021;9(8):4068–75. https://doi.org/10.1002/fsn3.2226.CrossRefPubMedPubMedCentral

38.

Hassaniazad M, Eftekhar E, Inchehsablagh BR, Kamali H, Tousi A, Jaafari MR, et al. A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients. Phytother Res. 2021;35(11):6417–27. https://doi.org/10.1002/ptr.7294.CrossRefPubMedPubMedCentral

39.

Honarkar Shafie E, Taheri F, Alijani N, Okhovvat AR, Goudarzi R, Borumandnia N, et al. Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: a randomized double-blind placebo-controlled trial. Phytother Res. 2022;36(2):1013–22. https://doi.org/10.1002/ptr.7374.CrossRefPubMed

40.

Tahmasebi S, Saeed BQ, Temirgalieva E, Yumashev AV, El-Esawi MA, Navashenaq JG, et al. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2. Life Sci. 2021;276:119437. https://doi.org/10.1016/j.lfs.2021.119437.CrossRefPubMedPubMedCentral

41.

Rattis BAC, Ramos SG, Celes MRN. Curcumin as a potential treatment for COVID-19. Front Pharmacol. 2021;12:675287. https://doi.org/10.3389/fphar.2021.675287.CrossRefPubMedPubMedCentral

42.

Sfera A, Osorio C, Del Campo CMZM, Pereida S, Maurer S, Maldonado JC, et al. Endothelial senescence and chronic fatigue syndrome, a COVID-19 based hypothesis. Front Cell Neurosci. 2021;15:673217. https://doi.org/10.3389/fncel.2021.673217.CrossRefPubMedPubMedCentral

43.

Wilson C. Concern coronavirus may trigger post-viral fatigue syndromes. New Sci (1971). 2020;246(3278):10. https://doi.org/10.1016/S0262-4079(20)30746-6.CrossRef

44.

Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis. 2021;53(10):1–18. https://doi.org/10.1080/23744235.2021.1924397.CrossRef

45.

Sun Y, Zhou J, Ye K. White blood cells and severe COVID-19: a Mendelian randomization study. medRxiv. 2020:2020.10.14.20212993. https://doi.org/10.1101/2020.10.14.20212993.

46.

Sarma P. Chapter 152. Red cell indices. In: Clinical methods: the history, physical, and laboratory examinations. 3rd ed. Boston: Butterworths; 1990.

47.

Strandberg O. CHAPTER VII: The influence of corticosteroid therapy on hematological values, bone marrow iron and iron absorption in patients with rheumatoid arthritis. Acta Med Scand. 1966;180(S454):127–41. https://doi.org/10.1111/j.0954-6820.1966.tb01372.x.CrossRef

48.

Bani-Sadr F, Hentzien M, Pascard M, N'Guyen Y, Servettaz A, Andreoletti L, et al. Corticosteroid therapy for patients with COVID-19 pneumonia: a before–after study. Int J Antimicrob Agents. 2020;56(2):106077. https://doi.org/10.1016/j.ijantimicag.2020.106077.CrossRefPubMedPubMedCentral

49.

Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416–20. https://doi.org/10.5694/mja2.50577.CrossRefPubMedPubMedCentral

50.

Smith TJ, Ashar BH. Iron deficiency anemia due to high-dose turmeric. Cureus. 2019;11(1):e3858. https://doi.org/10.7759/cureus.3858.CrossRefPubMedPubMedCentral

51.

Chin D, Huebbe P, Frank J, Rimbach G, Pallauf K. Curcumin may impair iron status when fed to mice for six months. Redox Biol. 2014;2:563–9. https://doi.org/10.1016/j.redox.2014.01.018.CrossRefPubMedPubMedCentral

52.

Sultana GS, Haque SA, Sultana T, Ahmed AN. Value of red cell distribution width (RDW) and RBC indices in the detection of iron deficiency anemia. Mymensingh Med J. 2013;22(2):370–6.PubMed

53.

Liu A, Cong J, Wang Q, Mei Y, Peng Y, Zhou M, et al. Risk of malnutrition is common in patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a cross-sectional study. J Nutr. 2021;151(nxab009):1591–6. https://doi.org/10.1093/jn/nxab009.CrossRefPubMed

54.

Hong N, Kim CO, Youm Y, Choi JY, Kim HC, Rhee Y. Elevated red blood cell distribution width is associated with morphometric vertebral fracture in community-dwelling older adults, independent of anemia, inflammation, and nutritional status: the Korean Urban Rural Elderly (KURE) study. Calcif Tissue Int. 2019;104(1):26–33. https://doi.org/10.1007/s00223-018-0470-9.CrossRefPubMed

55.

García-Escobar A, Grande Ingelmo JM. Red cell volume distribution width as another biomarker. Card Fail Rev. 2019;5(3):176–9. https://doi.org/10.15420/cfr.2019.13.1.CrossRefPubMedPubMedCentral

56.

Ford J. Red blood cell morphology. Int J Lab Hematol. 2013;35(3):351–7. https://doi.org/10.1111/ijlh.12082.CrossRefPubMed

57.

Hu X, Chen D, Wu L, He G, Ye W. Low serum cholesterol level among patients with COVID-19 infection in Wenzhou, China. SSRN Electron J. 2020. https://doi.org/10.2139/ssrn.3544826.

58.

Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. 2022 Mar 7.

59.

Ferguson JJA, Stojanovski E, MacDonald-Wicks L, Garg ML. Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial. Metabolism. 2018;82:22–35. https://doi.org/10.1016/j.metabol.2017.12.009.CrossRefPubMed

60.

Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, et al. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones. 2008;40(4):201–10.PubMed

61.

Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784. https://doi.org/10.1371/journal.pone.0240784.CrossRefPubMedPubMedCentral

62.

Çalıca Utku A, Budak G, Karabay O, Güçlü E, Okan HD, Vatan A. Main symptoms in patients presenting in the COVID-19 period. Scott Med J. 2020;65(4):127–32. https://doi.org/10.1177/0036933020949253.CrossRefPubMed

63.

Holbrook JH. Weakness and fatigue; 2011.

64.

Wang P-Y, Li Y, Wang Q. Sarcopenia: an underlying treatment target during the COVID-19 pandemic. Nutrition. 2021;84:111104. https://doi.org/10.1016/j.nut.2020.111104.CrossRefPubMed

65.

Alamdari N, O'Neal P, Hasselgren P-O. Curcumin and muscle wasting: a new role for an old drug? Nutrition. 2009;25(2):125–9. https://doi.org/10.1016/j.nut.2008.09.002.CrossRefPubMed

66.

Penner CG, Gang G, Wray C, Fischer JE, Hasselgren P-O. The transcription factors NF-κB and AP-1 are differentially regulated in skeletal muscle during sepsis. Biochem Biophys Res Commun. 2001;281(5):1331–6. https://doi.org/10.1006/bbrc.2001.4497.CrossRefPubMed

67.

Li Y-P, Reid MB. NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am J Phys Regul Integr Comp Phys. 2000;279(4):R1165–R70. https://doi.org/10.1152/ajpregu.2000.279.4.R1165.CrossRef

68.

Ladner KJ, Caligiuri MA, Guttridge DC. Tumor necrosis factor-regulated biphasic activation of NF-κB is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem. 2003;278(4):2294–303. https://doi.org/10.1074/jbc.M207129200.CrossRefPubMed

69.

Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh B-C, Lidov HG, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285–98. https://doi.org/10.1016/j.cell.2004.09.027.CrossRefPubMed

70.

Wyke S, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-κ B activation. Br J Cancer. 2004;91(9):1742–50. https://doi.org/10.1038/sj.bjc.6602165.CrossRefPubMedPubMedCentral

71.

Pawar KS, Mastud RN, Pawar SK, Pawar SS, Bhoite RR, Bhoite RR, et al. Oral curcumin with piperine as adjuvant therapy for the treatment of COVID-19: a randomized clinical trial. Front Pharmacol. 2021;12:1056. https://doi.org/10.3389/fphar.2021.669362.CrossRef

Title: The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial
Authors: Gholamreza Askari
Amirhossein Sahebkar
Davood Soleimani
Atena Mahdavi
Sahar Rafiee
Muhammed Majeed
Farzin Khorvash
Bijan Iraj
Mahshid Elyasi
Mohammad Hossein Rouhani
Mohammad Bagherniya
Publication date: 01-12-2022
Publisher: BioMed Central
Keyword: COVID-19
Published in: Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-022-06375-w

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial

Abstract

Background

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2022

PROPHYlactic Implantation of BIOlogic Mesh in peritonitis (PROPHYBIOM): a prospective multicentric randomized controlled trial

Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial

Prophylaxis in healthcare workers during a pandemic: a model for a multi-centre international randomised controlled trial using Bayesian analyses

Prospective preference assessment for the Comparison of Analgesic Regimen Effectiveness and Safety in Surgery (CARES) trial

A randomised controlled trial investigating the clinical and cost-effectiveness of Alpha-Stim AID cranial electrotherapy stimulation (CES) in patients seeking treatment for moderate severity depression in primary care (Alpha-Stim-D Trial)

Evaluation of a web-based randomized controlled trial educational intervention based on media literacy on preventing substance abuse among college students, applying the integrated social marketing approach: a study protocol